Could two new drugs boost chemo success in HER2-Low breast cancer?
NCT ID NCT07317778
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding the drugs SHR-A1811 and/or adebrelimab to standard chemotherapy can improve outcomes for people with HR-positive, HER2-low early-stage breast cancer. About 249 participants will receive either chemo alone, chemo plus adebrelimab, or a sequence of SHR-A1811, adebrelimab, and chemo before surgery. The main goal is to see if these combinations lead to a higher rate of complete tumor disappearance (pathological complete response) at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A1811 (Trastuzumab Rezetecan) and Adebrelimab (PD-L1 inhibitor)
What this could lead to
If successful, this could lead to a more effective neoadjuvant treatment for HR+/HER2-low early breast cancer, potentially increasing the chance of a complete response before surgery.
What could go wrong
This is an early phase II trial with a moderate size (249 participants). The combination may not improve outcomes over standard chemo and could have added side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, 100021, China